Global Epinephrine Market Overview:
According to the Asthma and Allergy Foundation of America, 2014, anaphylaxis is a severe life-threatening allergic reaction occurring at least 1 in every 50 people in the United States. Epinephrine also is known as adrenaline is a hormone and neurotransmitter produced by the adrenal glands. This hormone is used to alter the effect of anaphylaxis (life-threatening allergic reaction) and is used as the first line of treatment. Most of the patients suffering from anaphylaxis use Epinephrine Auto-Injectors and can be administered by a nonmedical person also. The Epinephrine injections are commonly used against life-threatening allergic reactions caused by medications, insect bites and stings. According to AMA, the Global Epinephrine market is expected to see growth rate of 11.0%
- Rising Incidence of Anaphylaxis Associated With Food Allergy
- The Increasing Number of Patients Susceptible To Allergic Reactions
- Increasing Demand for Automatic Injection Devices Leading to the Growth of Epinephrine Auto-Injectors Market
- The Launch of New Products Like Epipen By Companies
- Unavailability of Approved Drugs Due To the Increasing Number of Product Recalls by Various Developers
- Programs for Patientís Assistance Carried out for an Uninsured Person and Continuous Product Modification Resulting in Demand for Automatic Injection Devices
- Side Effects Caused By Epinephrine Medications
The market is fragmented by The manufacturers are focused on developing and commercializing innovative drugs and novel drug delivery systems of therapeutic molecules to improve patient quality of life and to cater the clinical shortcomings of the commercially available products. The players are also focused on the development new products such as Chlorofluorocarbon (CFC) free epinephrine auto-injectors.
Some of the key players profiled in the report are Mylan N.V.(United States), Pfizer, Inc. (United States), Teva Pharmaceuticals Industries Ltd. (Israel), Impax Laboratories, Inc. (United States), Kaleo, Inc. (United States), Adamis Pharmaceuticals Corporation (United States), Amphastar Pharmaceuticals (United States), Merit Pharmaceutical (United States), Tianjin Jinyao Group (China) and Bausch Health Companies (Canada). Additionally, following companies can also be profiled that are part of our coverage like ALK- Abello A/S (Denmark), Sandoz (Germany) and INSYS Therapeutics,Inc. (United States). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Epinephrine market by 2025. Considering Market by Route of Administration, the sub-segment i.e. Intravenous will boost the Epinephrine market. Considering Market by Ingredients, the sub-segment i.e. Epinephrine Acetate will boost the Epinephrine market.
On July 2018, Adamis Pharmaceutical Corp. has signed an agreement with Sandoz Inc. Under this agreement, Sandoz will commercialize Adamis Symjepi product for emergency treatment of allergic reactions (Type I) including anaphylaxis. and On February 2018, Adamis Pharmaceuticals Corp. announced the FDA approval to review the supplemental New Drug Application (sNDA) for low dose Symjepi product candidate which is applicable for emergency treatment of anaphylaxis. The dose (0.15mg) intended is applicable for patients weighing 33-65 pounds.
On August 2018, Teva Pharmaceuticals received the FDA approval for using first generic versions of EpiPen and EpiPen Jr in case of any emergency treatment of allergic reactions or in any anaphylactic condition for adults and pediatric patients weighing more than 33 pounds. and On July 2018, INSYS Therapeutics, Inc. demonstrated the results of their early clinical trial for their investigational epinephrine nasal spray acting as a needle-free, non-invasive, and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Epinephrine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Epinephrine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Physicians, Pharmaceutical companies, Government and Regulatory Bodies, Traders, Distributors, and Suppliers and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.